


Schema



N=142 (N=117 – Arms A, B, and C;
N=25 – Arm T)

Cycle = 3 weeks (21 days)

1. Pre – Registration (Step 0) is for the purpose of central review of patient’s molecular testing to determine treatment assignment.
2. Tumors must be known to be negative for EGFR or ALK mutations for patients with or without eligible molecular alterations. Patients with molecular alterations (MET exon 14 mutation, MET amplification, ROS1 rearrangement, RET rearrangement) must submit testing results per Section 4.1.4.2.
3. Randomization is 1:1:1 across Arms A, B, and C
4. Please refer to Section 5.1.3 for specific dosing guidelines.
5. Patients will continue on study treatment until progressive disease or until an adverse event requiring discontinuation occurs at which time patient would proceed to follow-up.
6. Patients remain in follow-up for 3 years per Section 5.8.